Intensifying Daunorubicin in Induction for Patients with Core Binding Factor Leukemia

This is a preview of subscription content, log in to check access.


  1. 1.

    Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173–4179.

    CAS  PubMed  Google Scholar 

  2. 2.

    Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767–3675.

    CAS  PubMed  Google Scholar 

  3. 3.

    Byrd JC, Ruppert AS, Mrozek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22:1087–1094.

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML trial. Blood. 1998;92: 2322–2333.

    CAS  PubMed  Google Scholar 

  5. 5.

    Usui N, Dobashi N, Kobayashi T, et al. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia. J Clin Oncol. 1998;16:2086–2092.

    CAS  PubMed  Google Scholar 

  6. 6.

    Usui N, Dobashi N, Asai O, et al. Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemia. Int J Hematol. 2002;76: 436–445.

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741–3750.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information



Corresponding authors

Correspondence to Nobuaki Dobashi or Yuko Yamaguchi or Osamu Asai or Shingo Yano or Hiroshi Osawa or Yuichi Yahagi or Yutaka Takei or Katsuki Sugiyama or Takeshi Saito or Noriko Usui.

About this article

Cite this article

Dobashi, N., Yamaguchi, Y., Asai, O. et al. Intensifying Daunorubicin in Induction for Patients with Core Binding Factor Leukemia. Int J Hematol 84, 463–464 (2006).

Download citation


  • Acute Myeloid Leukemia
  • Complete Remission
  • Clin Oncol
  • Daunorubicin
  • Peripheral Blood Stem Cell Transplantation